Amicus Therapeutics (NASDAQ:FOLD) Insider Sells $773,765.28 in Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Jeff Castelli sold 76,158 shares of the stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $10.16, for a total transaction of $773,765.28. Following the transaction, the insider owned 439,318 shares in the company, valued at approximately $4,463,470.88. The trade was a 14.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Amicus Therapeutics Trading Down 0.8%

NASDAQ:FOLD opened at $9.94 on Friday. The firm has a 50-day simple moving average of $8.79 and a 200-day simple moving average of $7.38. Amicus Therapeutics, Inc. has a one year low of $5.51 and a one year high of $10.57. The firm has a market cap of $3.07 billion, a P/E ratio of -82.78 and a beta of 0.66. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. The firm had revenue of $169.06 million for the quarter, compared to the consensus estimate of $165.24 million. Amicus Therapeutics had a negative net margin of 6.67% and a negative return on equity of 5.07%. The company’s quarterly revenue was up 19.5% on a year-over-year basis. During the same period last year, the firm earned $0.10 earnings per share. Amicus Therapeutics has set its FY 2025 guidance at EPS. Equities analysts anticipate that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Amicus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Osaic Holdings Inc. increased its position in shares of Amicus Therapeutics by 450.1% in the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 3,358 shares during the period. EverSource Wealth Advisors LLC grew its stake in Amicus Therapeutics by 472.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 3,677 shares during the last quarter. Strs Ohio acquired a new position in shares of Amicus Therapeutics in the first quarter valued at about $30,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Amicus Therapeutics in the third quarter worth about $31,000. Finally, Versant Capital Management Inc raised its stake in shares of Amicus Therapeutics by 499.1% in the third quarter. Versant Capital Management Inc now owns 5,266 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 4,387 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Needham & Company LLC upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research note on Thursday, September 18th. Zacks Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amicus Therapeutics in a research report on Tuesday. JPMorgan Chase & Co. increased their target price on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Finally, Wall Street Zen upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Amicus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $16.57.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.